Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
274,650,631
-
Total 13F shares
-
14,700,530
-
Share change
-
-2,290,617
-
Total reported value
-
$54,695,000
-
Put/Call ratio
-
0%
-
Price per share
-
$3.72
-
Number of holders
-
55
-
Value change
-
-$11,594,670
-
Number of buys
-
28
-
Number of sells
-
47
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock (TSHA) as of Q2 2022
As of 30 Jun 2022,
Taysha Gene Therapies, Inc. - Common Stock (TSHA) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,700,530 shares.
The largest 10 holders included
FMR LLC, Nantahala Capital Management, LLC, VANGUARD GROUP INC, BlackRock Inc., Artal Group S.A., FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, Alphabet Inc., RENAISSANCE TECHNOLOGIES LLC, and TYBOURNE CAPITAL MANAGEMENT (HK) LTD.
This page lists
55
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.